Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

BMC Psychiatry

Volumn 16, Issue 1, 2016, Pages

  Moncrieff, Joanna ^a   Azam, Kiran ^b   Johnson, Sonia ^a   Marston, Louise ^a   Morant, Nicola ^a   Darton, Katherine ^c   Wood, Neil ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NORTH EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c Mind   (United Kingdom)

Author keywords

Antipsychotic drugs; Decision making; Long term treatment; Patient participation; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL EFFECTIVENESS; CONSULTATION; CONTROLLED STUDY; DECISION SELF EFFICACY SCALE; DELUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION REVIEW TOOL; MOOD DISORDER; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT SATISFACTION; PILOT STUDY; PRESCRIPTION; PSYCHOSIS; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; MEDICATION COMPLIANCE; MENTAL HEALTH SERVICE; MIDDLE AGED; PATIENT EDUCATION; PROCEDURES; PSYCHOLOGY; PSYCHOTIC DISORDERS; QUESTIONNAIRE;

ADULT; ANTIPSYCHOTIC AGENTS; COMMUNITY MENTAL HEALTH SERVICES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT MEDICATION KNOWLEDGE; PATIENT SATISFACTION; PILOT PROJECTS; PSYCHOTIC DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 84976871502     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-016-0921-7     Document Type: Article

References (35)

1. Department of Health. Our Health, Our Care, Our Say. London: Department of Health; 2006.
2. Shepherd G, Boardman J, Slade M. Making Recovery a Reality. London: Sainsbury Centre for Mental Health; 2008.
3. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv. 2006;57:1636-9.
4. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
5. Healthcare Commission. Talking about medicines: The management of medicines in Trusts providing mental health services. London: Commission for Healthcare, Audit and Inspection; 2007.
6. National Institute for Mental Health England National Workforce Programme. Medicines Management: Everybody's Business. A guide for service users, carers, and health and social care practitioners. London: Department of Health; 2008.
7. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-47.
8. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063-71.
9. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120:102-11.
10. Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25:521-6.
11. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23:2305-12.
12. Seale C, Chaplin R, Lelliott P, Quirk A. Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations. Soc Sci Med. 2007;65:698-711.
13. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932-9.
14. Hamann J, Mendel RT, Fink B, Pfeiffer H, Cohen R, Kissling W. Patients' and psychiatrists' perceptions of clinical decisions during schizophrenia treatment. J Nerv Ment Dis. 2008;196:329-32.
15. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. London: NICE; 2014.
16. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry. 2005;162:2382-4.
17. Loh A, Kremer N, Giersdorf N, Jahn H, Hanselmann S, Bermejo I, et al. Information and participation interests of patients with depression in clinical decision making in primary care. Z Arztl Fortbild Qualitatssich. 2004;98:101-7.
18. Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M. The effects of a shared decision-making intervention in primary care of depression: a cluster-randomized controlled trial. Patient Educ Couns. 2007;67:324-32.
19. Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand. 2006;114:265-73.
20. Hamann J, Mendel R, Meier A, Asani F, Pausch E, Leucht S, et al. "How to speak to your psychiatrist": shared decision-making training for inpatients with schizophrenia. Psychiatr Serv. 2011;62:1218-21.
21. van der Krieke L, Emerencia AC, Boonstra N, Wunderink L, de Jonge P, Sytema S. A web-based tool to support shared decision making for people with a psychotic disorder: randomized controlled trial and process evaluation. J Med Internet Res. 2013;15:e216.
22. Woltmann EM, Wilkniss SM, Teachout A, McHugo GJ, Drake RE. Trial of an electronic decision support system to facilitate shared decision making in community mental health. Psychiatr Serv. 2011;62:54-60.
23. Stovell D, Morrison AP, Panayiotou M, Hutton P. Shared treatment decision-making and empowerment-related outcomes in psychosis: systematic review and meta-analysis. Br J Psychiatry. 2016: doi: 10.1192/bjp.bp.114.158931
24. O'Connor AM. User Manual- Decision Self Efficacy Scale. Ottowa Hospital Research Institute, 1-4. 2002. Ottawa: Ottowa Hospital Research Institute. Available from: https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decision_SelfEfficacy.pdf.
25. Ottowa Hospital Research Institute. Patient Decision Aids. https://decisionaid.ohri.ca/.17-4-2015. 24-6-0015. Accessed 1 July 2016.
26. Bunn H, O'Connor A. Validation of client decision-making instruments in the context of psychiatry. Can J Nurs Res. 1996;28:13-27.
27. Atkisson CC, Zwick R. The Client Satisfaction Questionnaire: Psychometric properties and correlations with service utilisation and psychotherapy outcome. Eval Program Plan. 1982;5:233-7.
28. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-83.
29. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650-3.
30. Yamamoto N, Inada T, Shimodera S, Morokuma I, Furukawa TA. Brief PANSS to assess and monitor the overall severity of schizophrenia. Psychiatry Clin Neurosci. 2010;64:262-7.
31. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
32. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand. 2000;101:119-24.
33. Corp IBM. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp; 2013.
34. Stata Statistical Software: Release 13. College Station, Tx: StataCopr LP; 2013.
35. Braun V, Clark V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.